International Scholarly Research Notices

Clinical Study

Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series

Table 3

Clinical response rates of patients with metastatic breast cancer treated with vinorelbine either as monotherapy or with trastuzumab.
 VNR mono; (%)95% CIVNR + TRZ; (%)95% CI
CR00–8.81 (4.5%)0–23.5
PR12 (25%)14.8–38.913 (59.1%)38.7–76.8
SD12 (25%)14.8–38.96 (27.3%)12.9–48.4
PD25 (50%)36.4–63.62 (9.1%)1.3–29.0
CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease, VNR mono: vinorelbine monotherapy, VNR + TRZ: vinorelbine and trastuzumab, and 95% CI: 95% confidence interval.